Published by
@ShahidNShah
@ShahidNShah
BioSymetrics blends AI insights with zebrafish experiments for drug discovery.
BioSymetrics’ Elion Machine Learning & Experimental Validation platform integrates machine learning and experimental validation for phenomics-driven drug discovery. Their patented Contingent AI offers insights from clinical data, while the Phenograph links data sources and predicts gene targets. Zebrafish models validate predictions due to genetic similarity, enabling rapid and scalable experimentation for high-content phenotypic readouts.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on May 2, 2024 at 3:55am